MISSISSAUGA, Ontario, Dec. 16, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that the TSX Venture Exchange (“TSX-V”) has accepted the Company’s Notice of Intention to Make a Normal Course Issuer Bid (the “NCIB”). Pursuant to the NCIB, BioSyent may purchase up to 690,000 of its common shares (“Shares”) over a 12-month period, representing approximately 6.07% of the... Read More

MISSISSAUGA, Ontario, Nov. 20, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q3) and nine months (YTD) ended September 30, 2024. Key highlights include: (CAD) Q3 2024 % Change vs. Q3 2023 YTD 2024 % Change vs. YTD 2023 Trailing Twelve Months (TTM) Sept 30, 2024 % Change vs. TTM Sept 30, 2023 Canadian Pharma Sales 8,303,074 +12 % 24,384,698 +13... Read More

MISSISSAUGA, Ontario, Nov. 20, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.045 per common share, payable in Canadian Dollars on December 16, 2024, to shareholders of record at the close of business on November 29, 2024. This fourth quarter 2024 dividend compares with the third quarter 2024... Read More

MISSISSAUGA, Ontario, Nov. 13, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and nine months ended September 30, 2024 on Wednesday, November 20, 2024 before market opening. A presentation on the Company’s third quarter and year-to-date 2024 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s... Read More

MISSISSAUGA, Ontario, Sept. 20, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc., has entered into an agreement to acquire certain assets enabling it to supply Tibelia ® , a tibolone-based hormone replacement therapy drug, to distributors worldwide. Under an Asset Purchase Agreement entered into with the trustees... Read More

MISSISSAUGA, Ontario, Aug. 26, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q2) and six months (H1) ended June 30, 2024. Key highlights include: (CAD) Q2 2024 % Change vs. Q2 2023 H1 2024 % Change vs. H1 2023 Trailing Twelve Months (TTM) June 30, 2024 % Change vs. TTM June 30, 2023 Canadian Pharma Sales 8,535,480 +11% 16,081,624 +14%... Read More

MISSISSAUGA, Ontario, Aug. 26, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.045 per common share, payable in Canadian Dollars on September 15, 2024, to shareholders of record at the close of business on September 4, 2024. This third quarter 2024 dividend compares with the second quarter 2024... Read More

MISSISSAUGA, Ontario, June 12, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc. (“BioSyent Pharma”), has entered into an agreement with a European partner for an exclusive license to register, market, sell and distribute a new endocrinology product in Canada. BioSyent Pharma and its European partner have agreed to... Read More

MISSISSAUGA, Ontario, May 16, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q1) ended March 31, 2024. Key highlights include: (CAD) Q1 2024 % Change vs. Q1 2023 Trailing Twelve Months (TTM) March 31, 2024 % Change vs. TTM March 31, 2023 Canadian Pharma Sales 7,546,144 18 % 30,689,349 16 % International Pharma Sales - 0 % 1,047,747 789 % Total... Read More

MISSISSAUGA, Ontario, May 16, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.045 per common share, payable in Canadian Dollars on June 15, 2024, to shareholders of record at the close of business on May 31, 2024. This second quarter 2024 dividend compares with the first quarter 2024 dividend of... Read More

MISSISSAUGA, Ontario, May 09, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months ended March 31, 2024 on Thursday, May 16, 2024 after market hours. A presentation on the Company’s first quarter 2024 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release. About... Read More

MISSISSAUGA, Ontario, April 23, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be attending the Planet MicroCap Showcase in Las Vegas, Nevada between April 30 th – May 2 nd at the Paris Hotel & Casino. Mr. René Goehrum, President and CEO of BioSyent, will attend a Fireside Q&A session for investors at the conference on Wednesday, May 1 st at 2:30pm PDT. Mr. Goehrum... Read More

MISSISSAUGA, Ontario, April 15, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc. (“BioSyent Pharma”), has extended its Exclusive License and Distribution Agreement with its European partner for the RepaGyn ® and Proktis-M ® products, extending BioSyent Pharma’s exclusive Canadian rights to these products until... Read More

MISSISSAUGA, Ontario, April 10, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be presenting at the upcoming 2024 Bloom Burton & Co. Healthcare Investor Conference. The conference will be held in Toronto at the Metro Toronto Convention Centre (North Building) on Tuesday, April 16 and Wednesday, April 17, 2024. Mr. René Goehrum, President and CEO of BioSyent, will... Read More

MISSISSAUGA, Ontario, April 03, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that FeraMAX ® is the #1 recommended iron supplement brand in Canada, based on a national survey of Canadian pharmacists and physicians ( 1) . This year marks the ninth consecutive year that FeraMAX ® has been awarded this vote of confidence from physicians and pharmacists across Canada, including those... Read More

MISSISSAUGA, Ontario, April 01, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent” or the “Company”, TSX Venture: RX) announces that Mr. René Goehrum, President and CEO of BioSyent, will be presenting in person at the LD Micro Invitational XIV Conference in New York City on Tuesday, April 9 th at 8:00am EDT. This presentation will also be live-streamed virtually. Mr. Goehrum will also be available to meet with investors on a... Read More

MISSISSAUGA, Ontario, March 27, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc . (“BioSyent” or the “Company”, TSX Venture: RX) announces that its Board of Directors has approved a grant of 66,020 Restricted Share Units “RSUs” to certain directors, officers, management, and employees of the Company pursuant to the Company’s Restricted Share Unit Plan (the “RSU Plan”). These RSUs will fully vest within three years on the third... Read More

MISSISSAUGA, Ontario, March 13, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the fourth quarter (Q4) and full year (FY) ended December 31, 2023. Key highlights include: (CAD) Q4 2023 % Change vs. Q4 2022 FY 2023 % Change vs. FY 2022 Canadian Pharma Sales 7,989,098 10 % 29,554,899 13 % International Pharma Sales 54,750 -54 % 1,047,747 53 % Total Company Sales... Read More

MISSISSAUGA, Ontario, March 06, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months and full year ended December 31, 2023 on Wednesday, March 13th after market hours. A presentation on the Company’s fourth quarter and full year 2023 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website... Read More

MISSISSAUGA, Ontario, Feb. 21, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that it has been named to the 2024 TSX Venture 50 list as one of the top performers on the TSX Venture Exchange. The TSX Venture 50 is an annual ranking of the top performing companies from the past year on the TSX Venture Exchange. The TSX Venture 50 recognizes the top 10 companies from... Read More

MISSISSAUGA, Ontario, Feb. 06, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.045 per common share, payable in Canadian Dollars on March 15, 2024, to shareholders of record at the close of business on February 29, 2024. This first quarter 2024 dividend of $0.045 per common share represents a 12.5%... Read More

MISSISSAUGA, Ontario , Dec. 13, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that the TSX Venture Exchange (“TSX-V”) has accepted the Company’s Notice of Intention to Make a Normal Course Issuer Bid (the “NCIB”). Pursuant to the NCIB, BioSyent may purchase up to 650,000 of its common shares (“Shares”) over a 12-month period, representing approximately 5.53% of the... Read More

MISSISSAUGA, Ontario, Nov. 20, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has commenced the first shipments of its new oncology supportive care product, Gelclair ® , to wholesalers in Canada. Gelclair ® is indicated for the relief of the painful symptoms of oral mucositis. Oral mucositis (mouth sores and / or ulcers) is... Read More

MISSISSAUGA, Ontario, Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q3) and nine months (YTD) ended September 30, 2023. Key highlights include: (CAD) Q3 2023 % Change vs. Q3 2022 YTD 2023 % Change vs. YTD 2022 Trailing Twelve Months (TTM) Sept 30, 2023 % Change vs. TTM Sept 30, 2022 Canadian Pharma Sales 7,432,361 17 % 21,565,801 14 %... Read More

MISSISSAUGA, Ontario, Nov. 15, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.04 per common share, payable in Canadian Dollars on December 15, 2023, to shareholders of record at the close of business on November 30, 2023. This fourth quarter 2023 dividend compares with the third quarter 2023... Read More

MISSISSAUGA, Ontario, Nov. 09, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and nine months ended September 30, 2023 on Thursday, November 16, 2023 before market hours. A presentation on the Company’s third quarter and year-to-date 2023 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s... Read More

MISSISSAUGA, Ontario, Oct. 18, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce the launch of menopauseinformation.ca , a comprehensive online platform designed to empower peri-menopausal and menopausal women across Canada. Menopause is a natural transition that every woman experiences, and understanding this transition is crucial for a smoother journey. The menopauseinformation.ca... Read More

MISSISSAUGA, Ontario, Aug. 22, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and six months ended June 30, 2023. Key highlights include: Second quarter (Q2) 2023 Total Company Net Revenues of $7,962,800 increased by 20% versus Q2 2022 First half (H1) 2023 Total Company Net Revenues of $14,445,494 increased by 6% versus H1 2022 Record Q2 2023 Canadian... Read More

MISSISSAUGA, Ontario, Aug. 22, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.04 per common share, payable in Canadian Dollars on September 15, 2023, to shareholders of record at the close of business on August 31, 2023. This third quarter 2023 dividend compares with the second quarter 2023 dividend... Read More

MISSISSAUGA, Ontario, Aug. 15, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and six months ended June 30, 2023 on Tuesday, August 22, 2023 after market close. A presentation on the Company’s second quarter and first half 2023 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the... Read More

MISSISSAUGA, Ontario, Aug. 08, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has commenced the first shipments of Inofolic ® to the Canadian marketplace. Inofolic ® is a natural health product, combining myo-inositol and folic acid in a... Read More

MISSISSAUGA, Ontario, July 06, 2023 (GLOBE NEWSWIRE) -- BioSyent Pharma Inc. (“BioSyent Pharma”), a subsidiary of BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX), is attending the American Head and Neck Society (AHNS) 11 th International Conference on Head and Neck Cancer in Montreal, Quebec on July 8-12, 2023 to promote Gelclair ® , its new oncology supportive care product. Gelclair ® , indicated for the relief... Read More

MISSISSAUGA, Ontario, June 20, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc. (“BioSyent Pharma”), has extended its License, Distribution and Supply Agreement with its European partner for the Cathejell ® product, extending BioSyent Pharma’s exclusive Canadian rights to Cathejell ® until 2034. “We have had... Read More

MISSISSAUGA, Ontario, May 31, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has received regulatory approval from Health Canada for a new oncology supportive care product. BioSyent Pharma Inc. signed an exclusive Canadian Distribution Agreement for this product with a European partner in December 2022. “We are pleased to... Read More

MISSISSAUGA, Ontario, May 26, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months ended March 31, 2023. Key highlights include: First quarter (Q1) 2023 Canadian Pharmaceutical Net Revenues of $6,411,694 increased by 1% versus Q1 2022 Q1 2023 International Pharmaceutical Net Revenues were $nil as compared to sales of $565,787 in Q1 2022 Q1 2023 Total... Read More

MISSISSAUGA, Ontario, May 25, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.04 per common share, payable in Canadian Dollars on June 15, 2023, to shareholders of record at the close of business on June 2, 2023. This second quarter 2023 dividend compares with the first quarter 2023 dividend of $0.04... Read More

MISSISSAUGA, Ontario, May 18, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months ended March 31, 2023 on Friday, May 26, 2023 at 8:00am ET. A presentation on the Company’s first quarter 2023 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release. About BioSyent... Read More

MISSISSAUGA, Ontario, May 02, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that FeraMAX ® is the #1 recommended iron supplement brand in Canada, based on a national survey of Canadian pharmacists and physicians ( 1) . This is the eighth consecutive year that FeraMAX ® has been awarded this vote of confidence. The annual Survey on OTC Counselling and Recommendations is an... Read More

MISSISSAUGA, Ontario, April 18, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be presenting at the upcoming 2023 Bloom Burton & Co. Healthcare Investor Conference. The conference will be held in Toronto at the Metro Toronto Convention Centre (North Building) on Tuesday, April 25 and Wednesday, April 26, 2023 between 8:30am and 4:30pm ET. Mr. René Goehrum, President... Read More

MISSISSAUGA, Ontario, March 31, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent” or the “Company”, TSX Venture: RX) announces that its Board of Directors has approved a grant of 72,020 Restricted Share Units “RSUs” to certain directors, officers, management, and employees of the Company pursuant to the Company’s Restricted Share Unit Plan (the “RSU Plan”). These RSUs will fully vest within three years on the third... Read More

MISSISSAUGA, Ontario, March 21, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and twelve months ended December 31, 2022. Key highlights include: Fourth quarter (Q4) 2022 Total Company Net Revenues of $7,461,930 increased by 3% versus Q4 2021 Q4 2022 Total Company Net Revenues from continuing brands increased by 15% versus Q4 2021 (excluding brands... Read More

MISSISSAUGA, Ontario, March 09, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months and full year ended December 31, 2022 on Tuesday, March 21, 2023 after market close. A presentation on the Company’s fourth quarter and full year 2022 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website... Read More

MISSISSAUGA, Ontario, March 07, 2023 (GLOBE NEWSWIRE) -- On the eve of International Women’s Day , BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) celebrates the Canadian launch of Fera MAX ® Pd Maintenance 45 by its subsidiary, BioSyent Pharma Inc. FeraMAX ® Pd Maintenance 45 is BioSyent’s third product... Read More

MISSISSAUGA, Ontario, Feb. 01, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.04 per common share, payable in Canadian Dollars on March 15, 2023, to shareholders of record at the close of business on February 28, 2023. This first quarter 2023 dividend compares with the fourth quarter 2022 dividend... Read More

MISSISSAUGA, Ontario, Dec. 14, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has signed an exclusive Distribution Agreement with a European partner for a product that is used in oncology supportive care. The product has been marketed in Europe, USA and several other markets around the world to help cancer patients with... Read More